139 related articles for article (PubMed ID: 27387685)
1. Fever Therapy With Intravenously Applied Mistletoe Extracts for Cancer Patients: A Retrospective Study.
Schläppi M; Ewald C; Kuehn JJ; Weinert T; Huber R
Integr Cancer Ther; 2017 Dec; 16(4):479-484. PubMed ID: 27387685
[TBL] [Abstract][Full Text] [Related]
2. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
[TBL] [Abstract][Full Text] [Related]
3. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.
Huber R; Schlodder D; Effertz C; Rieger S; Tröger W
BMC Complement Altern Med; 2017 Sep; 17(1):465. PubMed ID: 28923036
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Schad F; Atxner J; Buchwald D; Happe A; Popp S; Kröz M; Matthes H
Integr Cancer Ther; 2014 Jul; 13(4):332-40. PubMed ID: 24363283
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
6. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
7. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study.
Pelzer F; Tröger W; Nat DR
J Altern Complement Med; 2018; 24(9-10):954-961. PubMed ID: 30247950
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review.
Melzer J; Iten F; Hostanska K; Saller R
Forsch Komplementmed; 2009 Aug; 16(4):217-26. PubMed ID: 19729932
[TBL] [Abstract][Full Text] [Related]
9. [Mistletoe in the treatment of cancer patients].
Rostock M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 May; 63(5):535-540. PubMed ID: 32211937
[TBL] [Abstract][Full Text] [Related]
10. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
[TBL] [Abstract][Full Text] [Related]
11. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.
Schad F; Axtner J; Kröz M; Matthes H; Steele ML
Integr Cancer Ther; 2018 Mar; 17(1):41-51. PubMed ID: 29444603
[TBL] [Abstract][Full Text] [Related]
12. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study.
Bar-Sela G; Wollner M; Hammer L; Agbarya A; Dudnik E; Haim N
Eur J Cancer; 2013 Mar; 49(5):1058-64. PubMed ID: 23218588
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
14. Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs.
Weber K; Mengs U; Schwarz T; Hajto T; Hostanska K; Allen TR; Weyhenmeyer R; Lentzen H
Arzneimittelforschung; 1998 May; 48(5):497-502. PubMed ID: 9638318
[TBL] [Abstract][Full Text] [Related]
15. Mistletoe in conventional oncological practice: exemplary cases.
Legnani W
Integr Cancer Ther; 2008 Sep; 7(3):162-71. PubMed ID: 18956494
[TBL] [Abstract][Full Text] [Related]
16. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Eur J Med Res; 2008 Mar; 13(3):107-20. PubMed ID: 18499556
[TBL] [Abstract][Full Text] [Related]
17. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Forsch Komplementmed; 2006 Oct; 13(5):285-92. PubMed ID: 17057389
[TBL] [Abstract][Full Text] [Related]
18. Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series.
Zuzak TJ; Wasmuth A; Bernitzki S; Schwermer M; Längler A
Complement Ther Med; 2018 Oct; 40():198-202. PubMed ID: 30219449
[TBL] [Abstract][Full Text] [Related]
19. Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters.
Kienle GS; Grugel R; Kiene H
BMC Complement Altern Med; 2011 Aug; 11():72. PubMed ID: 21871125
[TBL] [Abstract][Full Text] [Related]
20. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Evid Based Complement Alternat Med; 2014; 2014():724258. PubMed ID: 24672577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
